DCM
ORMP icon

DAFNA Capital Management’s Oramed Pharmaceuticals ORMP Stock Holding History

DAFNA Capital Management’s Portfolio ORMP Stock Details ORMP Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-16,000
Closed -$51K – 85
2019
Q3 		$51K Hold
16,000
– – 0.02% 89
2019
Q2 		$57K Sell
16,000
-10,000
-38% -$35.3K 0.02% 85
2019
Q1 		$95K Buy
26,000
+10,000
+63% +$33.1K 0.04% 79
2018
Q4 		$48K Buy
+16,000
New +$66.2K 0.02% 82

Other funds holding ORMP

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Jane Street
Jane Street New York $777B AUM 61.18% 1-Year Est. Return
JSMC
Jess S. Morgan & Co Los Angeles, California $115M AUM 16.65% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
PNC Financial Services Group
PNC Financial Services Group Pittsburgh, Pennsylvania $173B AUM 20.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
RPC
Rossmore Private Capital Glastonbury, Connecticut $1.14B AUM 23.53% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

DAFNA Capital Management's ORMP Position: Q4 2019 in Review

DAFNA Capital Management sold out of Oramed Pharmaceuticals (ORMP) in Q4 2019, closing a stake of 16,000 shares — an estimated $51K sold.

DAFNA Capital Management first reported a position in ORMP in Q4 2018 and held it in 4 quarters. The position peaked at $95K in Q1 2019. 30 funds tracked by Wall St. Rank hold ORMP as of Q4 2019.

  • DAFNA Capital Management reported no remaining Oramed Pharmaceuticals position as of Q4 2019 after selling out during the quarter.
  • DAFNA Capital Management sold 16,000 Oramed Pharmaceuticals shares in Q4 2019, an estimated $51K.
  • DAFNA Capital Management first reported a position in Oramed Pharmaceuticals in Q4 2018 and held it in 4 quarters.
  • DAFNA Capital Management's Oramed Pharmaceuticals position peaked at $95K in Q1 2019.
  • 30 funds tracked by Wall St. Rank held Oramed Pharmaceuticals as of Q4 2019.

Based on DAFNA Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.